SCHEMBL22042899

SCHEMBL22042899

Cc1ccc2oc(CS)nc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.54
MAPT P10636 7/20 0.54
RAB9A P51151 10/20 0.53
NPC1 O15118 9/20 0.53
SMN1; SMN2 Q16637 7/20 0.53
ALDH1A1 P00352 7/20 0.53
HPGD P15428 6/20 0.53
HSD17B10 Q99714 5/20 0.53
TP53 P04637 3/20 0.53
CASP3 P42574 3/20 0.50
SENP7 Q9BQF6 3/20 0.50
SENP6 Q9GZR1 3/20 0.50
SENP8 Q96LD8 2/20 0.50
POLB P06746 1/20 0.50
NFKB1 P19838 3/20 0.48
NFKB2 Q00653 3/20 0.48
RELA Q04206 3/20 0.48
L3MBTL1 Q9Y468 2/20 0.45
USP2 O75604 1/20 0.44
MAPK10 P53779 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30612631 1.00 KDM4E (0.54) KDM4EMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL22042890 0.86 KDM4E (0.74) KDM4EMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL11328720 0.85 KDM4E (0.58) KDM4EMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL11332226 0.85 KDM4E (0.73) KDM4EMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL5542189 0.84 GAA (0.56) KDM4EMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL12394367 0.82 RAB9A (0.57) KDM4EMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL13986779 0.82 KDM4E (0.54) KDM4EMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL4063835 0.82 KDM4E (0.54) KDM4EMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL23176649 0.81 KDM4E (0.53) KDM4EMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL5538663 0.81 KDM4E (0.62) KDM4EMAPTRAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12195469-B2 Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-01-14 US disclosed
EP-3892623-B1 COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF KOREA RES INST CHEMICAL TECH (KR) 2024-07-10 EP disclosed
CN-113166161-B Compounds having PDE9A inhibiting activity and pharmaceutical uses thereof 韩国化学研究院 2023-10-27 CN disclosed
US-20220024932-A1 COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2022-01-27 US disclosed
US-20220024932-A1 COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2022-01-27 US disclosed
EP-3892623-A1 COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF Korea Research Institute of Chemical Technology (KR) 2021-10-13 EP disclosed
CN-113166161-A Compound with PDE9A inhibitory activity and pharmaceutical use thereof 韩国化学研究院 2021-07-23 CN disclosed
WO-2020116971-A1 COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF 한국화학연구원 2020-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12195469-B2 Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof PDE9A, PDE5A, PDE3A KDM4E 930/4885MAPT 3479/4885RAB9A 38/4885
US-20220024932-A1 COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF PDE9A, PDE5A, PDE3A KDM4E 930/4885MAPT 3479/4885RAB9A 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.